


US-based startup Alercell to launch DNA sequencing-based leukaemia diagnostic test

30 December 2022 | News

Alercell plays a significant role in preventative medicine, particularly in the detection and treatment of cancer



Alercell is all set to launch LENA Q51(R) in January 2023. A leukaemia diagnostic test based on sequencing DNA will detect up to 51 genes mutations in leukaemia patients.

Based in the United States, the startup also has manufacturing and storage facilities in Europe and Asia, extending its accessibility and reach around the globe.

By offering unique and accurate diagnostic solutions that enhance patient outcomes, Alercell aims to contribute to the fight against cancer. "Stopping it before it starts" is the cornerstone of the Alercell mission.

Until recently, a series of blood tests and a bone marrow biopsy were required when someone was "suspected" to have leukaemia. It costs thousands of dollars and takes somewhere between 6 and 9 weeks. With LENA Q51, all of this is avoided, and in just three hours using a qPCR machine, clinicians will be able to identify any gene mutations among 51 different genes.

The first methylation-based molecular diagnostic test for lung cancer, LENA S1®, will be made available by Alercell later in the first quarter of 2023. As an epigenetic regulator of gene expression, DNA methylation enables early diagnosis of lung cancer and very accurate localisation of the disease, if present. Alercell Neuroscience will make a formal announcement in early 2023.